List of Nucynta Er drug patents

Nucynta Er is owned by Collegium Pharm Inc.

Nucynta Er contains Tapentadol Hydrochloride.

Nucynta Er has a total of 9 drug patents out of which 2 drug patents have expired.

Expired drug patents of Nucynta Er are:

  • US11007156
  • USRE39593

Nucynta Er was authorised for market use on 25 August, 2011.

Nucynta Er is available in tablet, extended release;oral dosage forms.

Nucynta Er can be used as a method of titrating an opioid to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate; a method of titrating an opioid to manage neuropathic pain associated with diabetic peripheral neuropathy severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, management of neuropathic pain associated with diabetic peripheral neuropathy; relief of moderate to severe chronic pain, relief of moderate to severe chronic pain; management of neuropathic pain associated with diabetic peripheral neuropathy, management of neuropathic pain associated with diabetic peripheral neuropathy.

The generics of Nucynta Er are possible to be released after 22 September, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(5 months ago)

US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007156 COLLEGIUM PHARM INC Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
Oct, 2022

(3 months ago)

US8309060 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US8420056 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US8075872 COLLEGIUM PHARM INC Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US8114383 COLLEGIUM PHARM INC Abuse-proofed dosage form
Oct, 2024

(1 year, 8 months from now)

US11344512 COLLEGIUM PHARM INC Titration of tapentadol
Apr, 2028

(5 years from now)

US8536130 COLLEGIUM PHARM INC Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Sep, 2028

(5 years from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 25 August, 2011

Treatment: Relief of moderate to severe chronic pain; Management of neuropathic pain associated with diabetic peripheral neuropathy; A method of titrating an opioid to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate; A method of titrating an opioid to manage neuropathic pain associated with diabetic peripheral neuropathy severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of NUCYNTA ER before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic